ASPEN PHAR.UN.ADR /1 O.N. Total Assets
ASPEN PHAR.UN.ADR /1 O.N. total assets. Based on the latest financial reports, ASPEN PHAR.UN.ADR /1 O.N. (LDZU) holds total assets worth €128.04 Billion EUR (≈ $149.70 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LDZU cash flow metrics for how efficiently the company converts equity into cash flow.
Total Assets of ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
Total assets of ASPEN PHAR.UN.ADR /1 O.N. from 2022 to 2025. This chart illustrates how ASPEN PHAR.UN.ADR /1 O.N.'s total assets have evolved over time, based on quarterly financial data. See current stock price of ASPEN PHAR.UN.ADR /1 O.N. for real-time trading data and today's change.
ASPEN PHAR.UN.ADR /1 O.N. - Asset Composition Analysis
ASPEN PHAR.UN.ADR /1 O.N. Total Assets Breakdown (June 2025)
ASPEN PHAR.UN.ADR /1 O.N. total assets breakdown as of June 2025. ASPEN PHAR.UN.ADR /1 O.N.'s total assets of €128.04 Billion consist of 28.5% current assets and 71.5% non-current assets. Explore working capital to net assets of ASPEN PHAR.UN.ADR /1 O.N. to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.7% |
| Accounts Receivable | €10.65 Billion | 7.8% |
| Inventory | €18.01 Billion | 13.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €67.21 Billion | 49.5% |
| Goodwill | €5.20 Billion | 3.8% |
Asset Composition Trend (2022–2025)
This chart illustrates how ASPEN PHAR.UN.ADR /1 O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ASPEN PHAR.UN.ADR /1 O.N.'s current assets represent 28.5% of total assets in 2025, a decrease from 31.0% in 2022.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2025, down from 5.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, unchanged from 52.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 49.5% of total assets.
ASPEN PHAR.UN.ADR /1 O.N. Competitors by Total Assets
Key competitors of ASPEN PHAR.UN.ADR /1 O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.77 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥2.00 Billion |
ASPEN PHAR.UN.ADR /1 O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.64 | 2.35 | 1.81 |
| Quick Ratio | 2.66 | 1.25 | 1.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €41.56 Billion | €23.20 Billion | €19.78 Billion |
ASPEN PHAR.UN.ADR /1 O.N. - Advanced Valuation Insights
This section examines the relationship between ASPEN PHAR.UN.ADR /1 O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -2.3% |
| Total Assets | €135.89 Billion |
| Market Capitalization | $2.95 Billion USD |
Valuation Analysis
Below Book Valuation: The market values ASPEN PHAR.UN.ADR /1 O.N.'s assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ASPEN PHAR.UN.ADR /1 O.N.'s assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
The table below shows the annual total assets of ASPEN PHAR.UN.ADR /1 O.N. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €135.89 Billion ≈ $158.87 Billion |
-2.28% |
| 2024-06-30 | €139.06 Billion ≈ $162.58 Billion |
+3.56% |
| 2023-06-30 | €134.28 Billion ≈ $156.99 Billion |
+20.57% |
| 2022-06-30 | €111.38 Billion ≈ $130.21 Billion |
-- |
About ASPEN PHAR.UN.ADR /1 O.N.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more